AgomAb Therapeutics NV’s Quiet Period Set To Expire Tomorrow (NASDAQ:AGMB)

AgomAb Therapeutics’ (NASDAQ:AGMB) quiet period is set to expire on Wednesday, March 18th. AgomAb Therapeutics had issued 12,500,000 shares in its IPO on February 6th. The total size of the offering was $200,000,000 based on an initial share price of $16.00. During the company’s quiet period, insiders and underwriters that worked on the IPO are prevented from issuing any earnings forecasts or research reports for the company because of SEC regulations. Following the expiration of the company’s quiet period, it’s expected that the brokerages that served as underwriters on the stock will initiate research coverage on the company.

Analyst Ratings Changes

A number of analysts have weighed in on the stock. Wall Street Zen upgraded shares of AgomAb Therapeutics to a “hold” rating in a research report on Tuesday, February 17th. Zacks Research upgraded shares of AgomAb Therapeutics to a “hold” rating in a report on Wednesday, March 4th. JPMorgan Chase & Co. started coverage on AgomAb Therapeutics in a research note on Tuesday, March 3rd. They issued an “overweight” rating and a $32.00 price target for the company. Leerink Partners started coverage on AgomAb Therapeutics in a report on Tuesday, March 3rd. They set an “outperform” rating and a $36.00 price objective on the stock. Finally, Morgan Stanley started coverage on AgomAb Therapeutics in a research report on Tuesday, March 3rd. They set an “overweight” rating and a $28.00 price objective on the stock. Three investment analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company. According to data from MarketBeat, AgomAb Therapeutics currently has an average rating of “Moderate Buy” and an average target price of $32.00.

AgomAb Therapeutics Stock Performance

AgomAb Therapeutics stock opened at $14.31 on Tuesday. AgomAb Therapeutics has a 52-week low of $12.66 and a 52-week high of $17.45.

About AgomAb Therapeutics

AgomAb Therapeutics (NASDAQ: AGMB) is a biotechnology company focused on the discovery and development of monoclonal antibody therapeutics. The company’s name and stated strategy center on the creation of agonist antibodies designed to modulate specific receptor pathways, with the aim of providing disease-modifying treatments where conventional approaches have been limited. AgomAb’s work spans early-stage discovery through translational development and regulatory-directed studies.

AgomAb’s activities include antibody engineering, target validation, and progression of programs through preclinical and, when applicable, clinical development milestones.